Context
This topic ranges from serious neurologic conditions to everyday performance claims, so route, population, and study setting matter.
Compare Semax, Pinealon, DSIP/emideltide, and Epitalon across human studies, animal or cell research, route claims, and peptide-market use cases.
Peptides compared
Semax
A neuropeptide analog discussed for stroke, optic nerve disease, focus, mood, stress, and route choice, with mostly intranasal CNS-oriented published evidence and a weaker subcutaneous route narrative from clinic and anecdotal contexts.
Pinealon
A short EDR tripeptide discussed for neuroprotection, cognition, and sleep-adjacent claims, with support still concentrated in reviews, preclinical work, and unresolved source questions.
DSIP
A sleep-associated nonapeptide with older human insomnia studies, unresolved biology, and modern emideltide/DSIP claims that need careful source-by-source reading.
Epitalon
A short AEDG tetrapeptide discussed in circadian, melatonin, telomere, retina, and longevity contexts, where public claims often exceed direct clinical evidence.
Sources
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. Effectiveness of Semax in acute period of hemispheric ischemic stroke 1997.
PMID:11517472 Accessed 2026-06-08.
Russian-language controlled clinical trial in acute hemispheric ischemic stroke; route and regimen context require direct-source verification before any protocol display.
- 4.
PubMed. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke 2018.
doi:10.17116/jnevro20181183261-68 PMID:29798983 Accessed 2026-06-08.
Human stroke rehabilitation study reporting BDNF, motor-performance, and Barthel-index outcomes; keep regimen details study-reported only.
- 5.
PubMed. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease 2000.
PMID:10741256 Accessed 2026-06-08.
Russian-language clinical trial comparing intranasal drops, endonasal electrophoresis, and control groups in optic nerve disease.
- 6.
PubMed. Kinetics of Semax penetration into the brain and blood of rats after intranasal administration 2006.
doi:10.1134/s1068162006010055 PMID:16523722 Accessed 2026-06-08.
Rat tracer study supporting intranasal brain/blood exposure plausibility; not direct human efficacy evidence.
- 7.
doi:10.3390/molecules26010159 PMID:33396470 Accessed 2026-06-08.
Review of Glu-Asp-Arg/EDR mechanisms and neuroprotection claims; useful for mechanism mapping, not a sleep protocol source.
- 8.
PubMed. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes 2024.
doi:10.3390/ijms252111363 PMID:39518916 Accessed 2026-06-08.
In vitro induced-neuron study including EDR and AEDG; supports mechanism discussion but not clinical sleep or longevity claims.
- 9.
PubMed. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study 1992.
PMID:1299794 Accessed 2026-06-08.
Older human insomnia study; keep study context separate from protocol advice.
- 10.
PubMed. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs 1987.
PMID:3583493 Accessed 2026-06-08.
Older human sleep source; not a public dosing/protocol basis.
- 11.
PubMed. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells 2003.
PMID:12937682 Accessed 2026-06-08.
Human somatic cell source for telomerase/telomere mechanism; not a clinical longevity outcome.